Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Alterations in liver metabolism experienced by individuals with Down syndrome

22

Jan 2026

Alterations in liver metabolism experienced by individuals with Down syndrome

Researchers at the University of Colorado Anschutz Linda Crnic Institute for Down Syndrome (Crnic Institute) have uncovered compelling evidence that individuals with Down syndrome experience significant alterations in liver metabolism, including elevated levels of bile acids in the bloodstream and other biomarkers of liver dysfunction.

Medicare Advantage skews hospital readmission penalties

22

Jan 2026

Medicare Advantage skews hospital readmission penalties

For more than a decade, hospitals have worked to help older adults avoid repeated inpatient stays, incentivized by a federal program that cuts Medicare reimbursements if hospitals have higher-than-expected rates of readmissions for people with certain conditions.

Age-related changes in the gut microbiota impair intestinal stem cell function

22

Jan 2026

Age-related changes in the gut microbiota impair intestinal stem cell function

A new study led by Hartmut Geiger at the University of Ulm, Germany, and Yi Zheng and Kodandaramireddy Nalapareddy, Cincinnati Children's Hospital Medical Center (CCHMC), USA reveals that age-related changes in the gut microbiota directly impair intestinal stem cell (ISC) function and that restoring a youthful microbial environment can reverse this decline.

New ISSCR guidance charts path for pluripotent stem cell therapies

22

Jan 2026

New ISSCR guidance charts path for pluripotent stem cell therapies

The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of "Charting the Translational Pathway: ISSCR Best Practices for the Development of Pluripotent Stem Cell (PSC)-Derived Therapies," a new paper highlighting some of the most critical aspects of the ISSCR's breakthrough interactive resource designed to transform how PSC-derived therapies are developed, evaluated, and advanced toward clinical and commercial success.

Short naps refresh the brain for better learning

22

Jan 2026

Short naps refresh the brain for better learning

Even a short afternoon nap can help the brain recover and improve its ability to learn. In a study published on January 22, 2026, in the journal NeuroImage, researchers at the Medical Center - University of Freiburg, Geneva University Hospitals (HUG) and University of Geneva, show that even a nap is enough to reorganize connections between nerve cells so that new information can be stored more effectively.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.